Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioNTech
Biotech
BioNTech sees limited ADC benefit as ph. 3 shows modest efficacy
BioNTech saw modest efficacy and unexpected safety findings, leading the company to conclude its HER2-directed candidate may offer limited benefits.
Nick Paul Taylor
Oct 26, 2026 8:39am
ESMO: BMS’ Massacesi hails PD-L1xVEGF data as ‘very promising’
Oct 25, 2026 7:03pm
BioNTech’s mRNA cancer vaccine fails phase 3 test
Oct 13, 2026 8:48am
BioNTech sets survival standard in hard-to-treat cancer
Sep 14, 2026 4:15am
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
Aug 28, 2026 1:50pm
BioNTech brings in Sobi CEO—Chutes & Ladders
Aug 7, 2026 8:30am